- recruitingNA
The Dragon PLC Trial (DRAGON-PLC)
This study looks at a new way to prepare people with certain liver cancers for surgery. It compares a standard procedure (PVE) with a new one (PVE + HVE) to see if more people can have life-saving surgery and live longer.
United States · Australia · Austria - active not recruitingPHASE3
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
This study is testing a new medicine, Tinengotinib, for people with a type of bile duct cancer called cholangiocarcinoma. It's for those whose cancer has specific genetic changes (FGFR-altered) and hasn't responded to previous treatments, including an FGFR inhibitor drug. Researchers want to see if Tinengotinib is safe and works better than other treatments.
United States · Austria · Belgium - recruiting
A Simple Breath Test to Detect Liver Cancer and Monitor Liver Conditions
This study is testing a simple breath-test to find liver cancer earlier and check on other liver conditions. It looks for tiny chemicals in your breath. You could join if you have liver cancer, cirrhosis, or certain other liver issues, or tummy problems with a normal liver scan.
United Kingdom - active not recruitingPHASE2
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
This study looks at a drug called entrectinib for different types of advanced cancer. It focuses on cancers with specific genetic changes (NTRK, ROS1, or ALK gene fusions). Researchers want to see if entrectinib can help treat these cancers.
United States · Australia · Belgium - recruiting
In-Depth Characterisation of Biliary Strictures and Hepato-Pancreato-Biliary Focal Lesions for Development of New Technologies to Tackle Hepato-Pancreato-Biliary Cancers
This study aims to better understand cancers in the liver, bile ducts, and pancreas to find new ways to diagnose and treat them. Researchers are collecting samples to develop new technologies for earlier detection and more effective treatments for these challenging cancers.
United Kingdom - active not recruitingPHASE1, PHASE2
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
This study is testing a new cell therapy called gavo-cel for advanced cancers like mesothelioma and ovarian cancer. It explores how well gavo-cel works, both alone and with other cancer drugs, in people whose tumours produce a specific protein called mesothelin.
United States · Canada - recruiting
Ivosidenib in Locally Advanced or Metastatic Cholangiocarcinoma With IDH1 R132 Mutation After at Least One Prior Systemic Treatment - an Observational Study
This study looks at how a new drug, ivosidenib, works for people in Germany with a rare bile duct cancer that has a specific genetic change (IDH1 R132 mutation). It aims to see how well it works and if it's safe in real-life settings.
Germany - recruiting
Liver Cancer Registry Platform
This project is setting up a registry in Germany for people with liver cancers like HCC and cholangiocarcinoma. It will collect information on their health, treatments, and how they're feeling, to help doctors understand the diseases better and improve care in the future.
Germany - recruiting
Deep Liver Phenotyping and Immunology Study
This study aims to find better ways to spot liver cancers early, especially in people already at risk. Researchers are looking for clues in blood, urine, and liver samples that could show who might develop cancer, helping doctors treat it sooner.
United Kingdom - recruitingPHASE2
Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
This study looks at combining special medicines called immunotherapy with propranolol, and sometimes chemotherapy, for advanced pancreatic, liver, or bile duct cancers. It aims to see how safe and effective this new treatment approach is for patients.
Canada - active not recruitingPHASE3
Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer
This study looks into a new chemotherapy combination (gemcitabine and cisplatin) compared to the usual care (capecitabine or observation) for people with certain bile duct or gallbladder cancers after surgery. We want to see if the new combination works better.
Australia · Austria · Denmark - not yet recruitingNA
Endoscopic Radiofrequency Ablation for Unresectable Cholangiocarcinoma
This study looks at a treatment called radiofrequency ablation (RFA) for bile duct cancer that can't be removed by surgery. It aims to see if adding RFA to standard care (chemotherapy and stents) can reduce problems and is safe for patients.
Germany - recruitingPHASE2
Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma
This study is looking at a drug called ivosidenib for people with a type of bile duct cancer (cholangiocarcinoma) that has a specific gene change (IDH1 mutation). It aims to see if taking ivosidenib after standard chemotherapy and surgery can stop the cancer from coming back.
Germany - ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)
This study is testing a new drug, pemigatinib, against standard chemotherapy for a type of bile duct cancer (cholangiocarcinoma) that has spread or can't be removed, and has a specific gene change. It wants to see which treatment works better and is safer as a first treatment.
Germany · Belgium · Italy - recruitingPHASE3
An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma
This study looks at a daily tablet called ivosidenib for adults with bile duct cancer that has come back or spread, and has been treated before. It aims to confirm if the treatment is safe and works well, and how it affects quality of life.
Armenia · Australia · Austria